In vitro susceptibility of clinical isolates of Brucella melitensis to fucidic acid

Journal of Infection and Chemotherapy

Volumn 11, Issue 2, 2005, Pages 101-103

  Celik, Ilhami ^a,b   Cihangiroglu, Mustafa ^a   Denk, Affan ^a   Akbulut, Ayhan ^a  

^a FIRAT UNIVERSITY   (Turkey)

^b Cardiovascular Surgery   (Turkey)

Author keywords

Brucella melitensis; Fucidic acid; Susceptibility

Indexed keywords

FUSIDIC ACID;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD CULTURE; BONE MARROW CULTURE; BRUCELLA MELITENSIS; BRUCELLOSIS; CONTROLLED STUDY; DILUTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 18444385673     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-004-0363-x     Document Type: Article

References (15)

1. Corbel MJ. Brucellosis: an overview. Emerg Infect Dis 1997;3:213-21.
2. Trujillano-Martin I, Garcia-Sanchez E, Martinez IM, Fresnadillo MJ, Garcia-Sanchez JE, Garcia-Rodriguez JA. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother 1999;43:194-5.
3. Acocella G, Bertrand A, Beytout J, Durrande JB, Garcia Rodriguez JA, Kosmidis J, et al. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrob Chemother 1990;23:433-9.
4. García-Rodríguez JA, García Sánchez JE, Trujillano I, García Sánchez E, García García MI, Fresnadillo MJ. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob Agents Chemother 1995;39:1194-5.
5. Garcia-Rodriguez JA, Munoz Bellido JL, Fresnadillo MJ, Trujillano I. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob Agents Chemother 1993;37:911-13.
6. Collignon P, Turnidge J. Fucidic acid in vitro activity. Int J Antimicrob Agents 1999;12(Suppl 2):45-58.
7. Moyer NP, Holcomb LA, Brucella. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 6th ed. Washington, D.C: American Society for Microbiology; 1995; p. 549-55.
8. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibilitiy test for bacteria that grow aerobically: approved standard. 6th ed. Document M7-A5. Wayne, PA: NCCLS; 2003.
9. Nielsen SL, Black FT. The effect of dicloxacillin and fucidic acid on the extracellular and intracellular killing of Staphylococcus aureus. J Antimicrob Chemother 1998;42:221-6.
10. Roder BL, Forsgren A, Gutschik E. The effect of antistaphylococcal agents used alone and in combinations on the survival of Staphylococcus aureus ingested by human polymorphonuclear leukocytes. APMIS 1991;99:521-9.
11. Witzig RS, Franzblau SG. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fucidic acid. Antimicrob Agents Chemother 1993;37:1997-9.
12. Shapiro SD, Wong JD. Brucella. In: Murray P, editor. Manual of clinical microbiology, vol. 1. 7th ed. Washington DC. ASM; 1999; 525-31.
13. Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, Orrantia-Gradin R, Hernandez-Oliva GM, Torres Y; et al. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis 2004;36:636-8.
14. Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004;23:405-7.
15. Kocagoz S, Akova M, Altun B, Gur D, Hascelik G. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect 2002;8:240-2.